XOMA (NASDAQ:XOMA) Upgraded at StockNews.com

XOMA (NASDAQ:XOMA - Get Free Report) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Friday.

Separately, HC Wainwright reiterated a "buy" rating and issued a $104.00 price objective on shares of XOMA in a report on Friday, March 28th.

XOMA Stock Down 2.4 %

Shares of XOMA stock traded down $0.51 during trading hours on Friday, reaching $20.30. 412 shares of the company were exchanged, compared to its average volume of 37,645. The firm has a market cap of $242.59 million, a PE ratio of -5.83 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA has a 1 year low of $18.35 and a 1 year high of $35.00. The stock's fifty day moving average is $21.91 and its 200 day moving average is $26.13.

XOMA (NASDAQ:XOMA - Get Free Report) last issued its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The firm had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, equities research analysts forecast that XOMA will post -1.41 earnings per share for the current year.

Remove Ads

Insider Buying and Selling

In other news, Director Joseph M. Limber acquired 5,243 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was acquired at an average cost of $25.60 per share, with a total value of $134,220.80. Following the completion of the acquisition, the director now owns 10,000 shares of the company's stock, valued at $256,000. The trade was a 110.22 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CIO Bradley Sitko bought 2,000 shares of the business's stock in a transaction dated Monday, April 7th. The stock was acquired at an average cost of $24.70 per share, for a total transaction of $49,400.00. Following the completion of the acquisition, the executive now directly owns 5,045 shares in the company, valued at approximately $124,611.50. This trade represents a 65.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 29,312 shares of company stock worth $735,061 in the last quarter. 7.20% of the stock is owned by insiders.

Institutional Investors Weigh In On XOMA

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its position in XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock valued at $4,840,000 after acquiring an additional 1,138 shares during the period. Woodline Partners LP increased its holdings in shares of XOMA by 63.9% in the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company's stock valued at $4,107,000 after purchasing an additional 60,927 shares during the period. State Street Corp raised its stake in shares of XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock worth $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Eversept Partners LP lifted its holdings in shares of XOMA by 1.2% during the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock worth $2,508,000 after purchasing an additional 1,128 shares during the period. Finally, Northern Trust Corp grew its position in XOMA by 1.5% in the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after buying an additional 1,340 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company's stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.